Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status
Oncotarget · 2024
DOI: 10.18632/oncotarget.28602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncotarget, 2024. Verfasst von Jun Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Hauptthemen laut MEDLINE: Trifluridine, Phenylurea Compounds, Pyridines, Drug Synergism. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
- Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, RI 02912, USA.
- Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, RI 02912, USA.
- The Joint Program in Cancer Biology, Brown University and Lifespan Health System, RI 02912, USA.
- Cancer Center at Brown University, Warren Alpert Medical School, Brown University, RI 02912, USA.
- Hematology-Oncology Division, Department of Medicine, Lifespan Health System and Warren Alpert Medical School, Brown University, RI 02912, USA.
Zitieren
APA
Zhang, J., Zhou, L., Zhao, S., & El-Deiry, W. S. (2024). Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status. Oncotarget. https://doi.org/10.18632/oncotarget.28602
Vancouver
Zhang J, Zhou L, Zhao S, El-Deiry WS. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status. Oncotarget. 2024. doi:10.18632/oncotarget.28602
BibTeX
@article{Zhang2024,
author = {Zhang, Jun and Zhou, Lanlan and Zhao, Shuai and El-Deiry, Wafik S},
title = {Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status},
journal = {Oncotarget},
year = {2024},
doi = {10.18632/oncotarget.28602}
}
EUVIMED